Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells, Cancer Research, September 2014, American Association for Cancer Research (AACR),
DOI: 10.1158/1538-7445.am2014-4556.
You can read the full text:

Read

Contributors

The following have contributed to this page